Marinus Pharmaceuticals has entered into a definitive agreement to sell its rare pediatric disease priority review voucher for $110 million to Novo Nordisk.
The identity of the buyer was disclosed in documents Radnor-based Marinus (NASDAQ: MRNS) filed with the Securities and Exchange Commission. Novo Nordisk (NYSE: NVO) is a Danish pharmaceutical company focused on diabetes and other serious chronic diseases such as obesity and rare blood and rare endocrine diseases. It has its U.S. headquarters…
